Dr Heinrich is a consultant to MolecularMD, Novartis, Pfizer, and Blueprint Medicines; has received speakers honorarium from Novartis and Pfizer; holds equity interest in MolecularMD (nonpublic); has received research funding from Blueprint Medicines, Deciphera Pharmaceuticals, and Inhibikase; holds intellectual property in the form of a patent licensed to Novartis (royalty to Oregon Health and Science University Knight Cancer Institute); and has provided expert testimony (patent litigation) for Novartis. Dr Demetri is a consultant for Novartis, Pfizer, Daiichi-Sankyo, Blueprint Medicines, Kolltan Pharmaceuticals, and Caris Life Sciences; holds equity interest in Blueprint Medicines (public), Kolltan Pharmaceuticals (private), and Caris Life Sciences (public); has received research funding from Novartis, Bayer, and Pfizer; holds intellectual property in the form of a patent licensed to Novartis (royalty to Dana-Farber Cancer Institute); scientific advisory board member for Blueprint Medicines; and board of directors for Blueprint Medicines. No other disclosures are reported.